Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Cancer Res. 2012 Feb 8;18(7):1947–1953. doi: 10.1158/1078-0432.CCR-11-2511

Figure 3.

Figure 3

Distribution of driver mutations according to adenocarcinoma histological subtypes. All the adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) harbored EGFR mutations. Significantly higher frequency of KRAS (14.3% versus 1.5%; p=0.028) and HER2 (21.4% versus 3.9%; p=0.021) mutations was found in invasive mucinous adenocarcinoma (IMA). Frequency of EGFR mutations was positively associated with acinar predominant tumors (83.1% versus 68.7%; p=0.002), and negatively with IMA (28.6% versus 78.2%; p<0.001) and solid predominant tumors (60.9% versus 78.5%; p=0.009).